FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:955-957 September 2, 2004 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Since December 2003, the National Institutes of Health (NIH) has been battered by accounts of the outside financial arrangements between some of its employees and pharmaceutical companies — and hence by concerns that the NIH ethics program is not working.^1,2 Having "reached the conclusion that drastic changes are needed," Dr. Elias Zerhouni, the NIH director, plans to implement prohibitions and restrictions on many of these payments and new requirements for public disclosure of those that are still allowed. Zerhouni is "working to strike a careful balance."³ He does not plan to ban all drug-industry payments to institute scientists. A ban . . . [Full Text of this Article]

This article has been cited by other articles:

• Claxton, L. (2007). A review of conflict of interest, competing interest, and bias for toxicologists. Toxicol Ind Health 23: 557-571 [Abstract]  
• Camilleri, M., Gamble, G. L., Kopecky, S. L., Wood, M. B., Hockema, M. L. (2005). Principles and Process in the Development of the Mayo Clinic's Individual and Institutional Conflict of Interest Policy. Mayo Clin Proc. 80: 1340-1346 [Abstract]  
• Steinbrook, R. (2005). Standards of Ethics at the National Institutes of Health. NEJM 352: 1290-1292 [Full Text]